<DOC>
	<DOC>NCT00698789</DOC>
	<brief_summary>Determine the effect of treatment with INCB019602 administered as an add-on to stable dose metformin therapy in type 2 diabetic subjects on safety and glycemic control.</brief_summary>
	<brief_title>Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Established diagnosis of T2D Currently taking metformin monotherapy at a stable dose level FPG between 150 and 270 mg/dL History or clinical manifestations of renal impairment Hyperglycemia &gt; 270 mg/dL Receiving thiazolidenediones, Exenatide or sulfonylureas within 90 days prior to screening Prior use of Acipimox which is known under the name Olbetam within 90 days prior to screening. Diagnosed major depression within the last 2 years requiring hospitalization History of chronic insulin therapy for glycemic control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>